| HOME >> BIOLOGY >> TECHNOLOGY |
Total liabilities and stockholders'
equity $4,565,707 $5,854,868
WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES
(A Development Stage Company)
Condensed Consolidated Balance Sheets (Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
2008 2007 2008 2007
Revenues $197,951 $6,700 $556,442 $67,460
Cost of sales 73,956 1,770 206,021 23,544
Gross margin 123,995 4,930 350,421 43,916
Operating expenses:
Sales and marketing 328,289 277,248 1,008,969 567,218
Research and development 1,205,511 728,288 3,503,573 1,489,994
General and
administrative 648,966 773,656 1,971,773 1,582,812
Total operating
expenses 2,182,766 1,779,192 6,484,315 3,640,024
Operating loss (2,058,771) (1,774,262) (6,133,894) (3,596,108)
Other income and (expenses):
Interest income 16,709 82,960 66,490 98,741
Interest expense (4,957) (308) (12,182) (186,834)
Miscellaneous expense (23,298) -- (26,239) --
Total other income and
(expenses) (11,546) 82,652 28,069 (88,093)
Net loss before provision
for income taxes (2,070,317) (1,691,610) (6,105,825) (3,684,201)
Provision for income taxes -- -- -- --
Net loss (2,070,317) (1,691,610) (6,105,825) (3,684,201)
Accretion on Redeemable
Preferred Stock (
'/>"/>
| SOURCE WaferGen Biosystems, Inc. Copyright©2008 PR Newswire. All rights reserved |